APA (7th ed.) Citation

Razia, D., Hu, C., Cherrier, L., Nasar, A., Walia, R., & Tokman, S. (2022). Carfilzomib versus rituximab for treatment of de novo donor-specific antibodies in lung transplant recipients. Transplant Immunology, 75, 1. https://doi.org/10.1016/j.trim.2022.101703

Chicago Style (17th ed.) Citation

Razia, Deepika, Chengcheng Hu, Lauren Cherrier, Aasya Nasar, Rajat Walia, and Sofya Tokman. "Carfilzomib Versus Rituximab for Treatment of De Novo Donor-specific Antibodies in Lung Transplant Recipients." Transplant Immunology 75 (2022): 1. https://doi.org/10.1016/j.trim.2022.101703.

MLA (9th ed.) Citation

Razia, Deepika, et al. "Carfilzomib Versus Rituximab for Treatment of De Novo Donor-specific Antibodies in Lung Transplant Recipients." Transplant Immunology, vol. 75, 2022, p. 1, https://doi.org/10.1016/j.trim.2022.101703.